Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
PHIO PHARMACEUTICALS CORP (PHIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.85-5.64%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PHIO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operations remains above -$4.0 million | Phio aims to manage losses and negative cash flow. | Broken | Cash from operations falls below -$4.0 million in 2026-Q1 | Cash from operations: $-4.035M FY2026-Q2; GAAP. Published target: >= -4.0 million USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-4,035,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage biotechnology, not an established earnings compounder. The long-term thesis is on watch: PH-762 has reached planned development milestones, but recent financial performance is weak and the company remains loss-making.
The evidence snapshot does not provide a valuation measure or specific market expectations, so whether the shares are cheap or expensive versus peers cannot be assessed. The available evidence points to a high-risk setup, with no clear basis to say what clinical progress or future results are already reflected in valuation.
Near term, losses and cash use remain important concerns. Cash declined from $21.0 million at 2025-Q4 to $13.0 million at 2026-Q2, while management expects funds to support operations into the second half of 2027. Over the multi-year view, management has completed the PH-762 Phase 1b trial, submitted an FDA briefing package, and plans to start Phase 2b in Q1 2027, though the next-quarter miss risk is elevated.
The thesis depends on PH-762 advancing through planned clinical and regulatory steps while cash lasts long enough to support development. A guidance cut or weaker economic data could add pressure, while stronger results and guidance from healthcare bellwethers could improve the sector backdrop.
Over the next one to three years, PHIO's long-term thesis rests on clinical execution and cash management, with substantial uncertainty from ongoing losses and elevated near-term risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “General and Administrative Expenses General and administrative expenses for the three months ended June 30, 2026 were $1.2 million, a decrease of $49 thousand or 4%, compared with the three months ended June 30, 2025.” “Net Loss Net loss was $ 4.1 million for the three months ended June 30, 2026 as compared with $2.2 million for the three months ended June 30, 2025.”
Net income remains above -$4.0 million | Phio aims to manage losses and negative cash flow. | Broken | Net income falls below -$4.0 million in 2026-Q1 | Net income: $-4.138M FY2026-Q2; GAAP. Published target: >= -4.0 million USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-4,138,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “General and Administrative Expenses General and administrative expenses for the three months ended June 30, 2026 were $1.2 million, a decrease of $49 thousand or 4%, compared with the three months ended June 30, 2025.” “Net Loss Net loss was $ 4.1 million for the three months ended June 30, 2026 as compared with $2.2 million for the three months ended June 30, 2025.” Delivery assessment Nov 4, 2026 |
Operating income remains above -$4.17 million | Phio aims to manage losses and negative cash flow. | Broken | Operating income falls below -$4.17 million in 2026-Q1 | Operating income: $-4.268M FY2026-Q2; GAAP. Published target: >= -4.17 million USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-4,268,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “General and Administrative Expenses General and administrative expenses for the three months ended June 30, 2026 were $1.2 million, a decrease of $49 thousand or 4%, compared with the three months ended June 30, 2025.” “Net Loss Net loss was $ 4.1 million for the three months ended June 30, 2026 as compared with $2.2 million for the three months ended June 30, 2025.” Delivery assessment Nov 4, 2026 |
Raise approximately $21.3 million by mid-2027 | The company has a new $21.3 million funding target for mid-2027. | Intact | Funding falls short of $21.3 million by mid-2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.86 → $-0.61 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.86 | Unavailable | 2 / 0 |
| 2026-07-25 | $-0.86 | Unavailable | 2 / 0 |
| 2026-07-26 | $-0.88 | Unavailable | 2 / 0 |
| 2026-07-27 | $-0.88 | Unavailable | 2 / 0 |
| 2026-07-28 | $-0.88 | Unavailable | 2 / 0 |
| 2026-07-29 | $-0.88 | Unavailable | 2 / 0 |
| 2026-07-30 | $-0.86 | $0 | 2 / 2 |
| 2026-07-31 | $-0.86 | $0 | 2 / 2 |
| 2026-08-01 | $-0.88 | Unavailable | 2 / 0 |
| 2026-08-02 | $-0.86 | $0 | 2 / 2 |
| 2026-08-03 | $-0.86 | $0 | 2 / 2 |
| 2026-08-04 | $-0.88 | Unavailable | 2 / 0 |
| 2026-08-05 | $-0.86 | $0 | 2 / 2 |
| 2026-08-06 | $-0.88 | Unavailable | 2 / 0 |
| 2026-08-07 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-08 | $-0.86 | $0 | 2 / 2 |
| 2026-08-09 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-10 | $-0.86 | $0 | 2 / 2 |
| 2026-08-12 | $-0.63 | $0 | 2 / 2 |
| 2026-08-13 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-14 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-15 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-16 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-17 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-18 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-19 | $-0.86 | Unavailable | 2 / 0 |
| 2026-08-20 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-21 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-22 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-23 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-24 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-25 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-26 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-27 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-28 | $-0.45 | Unavailable | 2 / 0 |
| 2026-08-29 | $-0.61 | Unavailable | 2 / 0 |
| 2026-08-30 | $-0.61 | Unavailable | 2 / 0 |
| 2026-08-31 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-01 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-02 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-03 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-04 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-05 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-06 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-07 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-08 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-09 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-10 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-11 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-12 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-13 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-14 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-15 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-16 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-17 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-18 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-19 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-20 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-21 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-22 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-23 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-24 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-25 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-26 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-27 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-28 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-29 | $-0.61 | Unavailable | 2 / 0 |
| 2026-09-30 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-01 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-02 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-03 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-04 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-05 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-06 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-07 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-08 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-09 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-10 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-11 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-12 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-13 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-14 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-15 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-16 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-17 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-18 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-19 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-20 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-21 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-22 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-23 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-24 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-25 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-26 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-27 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-28 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-29 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-30 | $-0.61 | Unavailable | 2 / 0 |
| 2026-10-31 | $-0.61 | Unavailable | 2 / 0 |
| 2026-11-01 | $-0.61 | Unavailable | 2 / 0 |
| 2026-11-02 | $-0.61 | Unavailable | 2 / 0 |
| 2026-11-03 | $-0.61 | Unavailable | 2 / 0 |
| 2026-11-04 | $-0.61 | Unavailable | 2 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.